Skip to main content
Premium Trial:

Request an Annual Quote

Response Biomedical's Q1 Revenues Jump 67 Percent

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Response Biomedical today announced its first-quarter revenues rose 67 percent year over year to C$2.5 million ($2.6 million).

The C$2.5 million figure compares to C$1.5 million in revenues from a year ago. Clinical product revenues increased to C$1.8 million from C$1.2 million, while non-clinical product revenues climbed to C$266,285 from C$188,125 a year ago. Contract service revenues rose to C$448,104 from C$146,945 a year ago.

The firm's net loss for the quarter dropped 48 percent to C$1.4 million, or C$.04 per share, compared to C$2,660,048, or C$.10 per share.

As of March 31, Response Biomedical had a working capital balance of C$5.6 million.

In September, the Vancouver, British Columbia-based diagnostics test firm announced plans to cut costs by about C$2 million, and as part of that effort, said it would reduce its workforce by about 25 percent. In a statement today, CEO S. Wayne Kay said that the benefits of the restructuring effort had a material effect on the company's finances.

"The significant reduction in our workforce and the focus on our cardiac business are reflected not only in significantly reduced costs but also in increased sales volume," he said. The company did not disclose any of its costs, however, including R&D and SG&A spending.

The Scan

UK Pilot Study Suggests Digital Pathway May Expand BRCA Testing in Breast Cancer

A randomized pilot study in the Journal of Medical Genetics points to similar outcomes for breast cancer patients receiving germline BRCA testing through fully digital or partially digital testing pathways.

Survey Sees Genetic Literacy on the Rise, Though Further Education Needed

Survey participants appear to have higher genetic familiarity, knowledge, and skills compared to 2013, though 'room for improvement' remains, an AJHG paper finds.

Study Reveals Molecular, Clinical Features in Colorectal Cancer Cases Involving Multiple Primary Tumors

Researchers compare mismatch repair, microsatellite instability, and tumor mutation burden patterns in synchronous multiple- or single primary colorectal cancers.

FarGen Phase One Sequences Exomes of Nearly 500 From Faroe Islands

The analysis in the European Journal of Human Genetics finds few rare variants and limited geographic structure among Faroese individuals.